SCHEMBL4860072

SCHEMBL4860072

CC(C)(C)OC(=O)N1CCN(C(=O)OCc2ccccc2)CC1CCOc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.58
▸ PDK1 Q15118 1/20 0.46
▸ PDK2 Q15119 1/20 0.46
▸ PDK3 Q15120 1/20 0.46
▸ PDK4 Q16654 1/20 0.46
▸ OPRK1 P41145 1/20 0.43
▸ NR1H2 P55055 2/20 0.42
▸ NR1H3 Q13133 2/20 0.42
▸ ABHD6 Q9BV23 1/20 0.42
▸ DAGLA Q9Y4D2 1/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ HTT P42858 1/20 0.42
▸ PRMT5 O14744 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KLK7 P49862 1/20 0.42
▸ BCL9 O00512 1/20 0.41
▸ CTNNB1 P35222 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4860080 1.00 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL13340759 1.00 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL13705162 0.95 PARP1 (0.57) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8123475 0.94 PARP1 (0.55) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8112397 0.94 PARP1 (0.54) PARP1PDK1PDK2PDK3PDK4
SCHEMBL13705541 0.92 PARP1 (0.53) PARP1PDK1PDK2PDK3PDK4
SCHEMBL13705115 0.92 PARP1 (0.53) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8123342 0.91 PARP1 (0.52) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8113623 0.91 PARP1 (0.53) PARP1PDK1PDK2PDK3PDK4
SCHEMBL13705543 0.91 PARP1 (0.53) PARP1PDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405217-B2 N-aroyl piperazine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2008-07-29 — — US disclosed
US-20070167457-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC 2007-07-19 — — US disclosed
US-7166608-B2 N-aroyl piperazine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2007-01-23 — — US disclosed
US-20040242575-A1 N-aroyl piperazine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2004-12-02 — — US disclosed
EP-1434583-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-07-07 — — EP disclosed
WO-2003032991-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2003-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242575-A1 N-aroyl piperazine derivatives as orexin receptor antagonists HCRTR2, HCRTR1, CNR1 PARP1 3197/4885PDK1 3688/4885PDK2 2788/4885
US-20070167457-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 PARP1 3413/4885PDK1 2302/4885PDK2 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback